Drug intelligence / Profile preview

Imusurge

Development stage: Unknown
Lead developer: Obsurge Biotech
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**Imusurge** is an oral Ayurvedic herbal OTC tablet marketed by Obsurge as an immune-support product. Each 750 mg tablet contains extracts of tulsi, giloy, papaya, amla, punarnava, and haldi, along with babul gond. The official product page provides composition and tablet pack sizes but does not describe a validated molecular target, pharmacologic mechanism, or disease-specific clinical development program. ([obsurge.com](https://www.obsurge.com/product-details/otc/imusurge))

Brand names: Imusurge
Other names: Imusurge Immune Booster

Beyond the preview

Go deeper on Imusurge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imusurge.

Explore the full profile